

Zdroje

- Ablett, J. (2021). Integration Using Mandalas. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- ACT Counselling & CBT Services. (n.d.). *ACT Counselling*. <https://actcounselling.com>
- Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. *Neuroscience & Biobehavioral Reviews*, 113, 179–189.
- Adel, L., Mosese, L., Irvine, E., Greenway, K. T., Dumase, G., & Lifshitzb, M. (2012). Interpersonal neural synchrony as a mechanism of therapeutic alliance? A systematic review of. *Psychotherapy*, 1(4), 0.
- Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024). Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis. *Journal of Humanistic Psychology*, 64(4), 564–591.
- Aicher, H. (2024). *Advancements and challenges in psychedelic-assisted psychotherapy: insights from Swiss practice and therapist training* [přednáška]. ICPR conference, Haarlem.
- Aixalà, M., & Bouso, J. C. (2022). *Psychedelic Integration: Psychotherapy for Non-Ordinary States of Consciousness*. Synergetic Press. <https://books.google.cz/books?id=0AzdzgEACAAJ>
- Aleksandrova, L. R., & Phillips, A. G. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. *Trends in pharmacological sciences*, 42(11), 929–942.
- Allen, J. G., Romate, J., & Rajkumar, E. (2021). Mindfulness-based positive psychology interventions: a systematic review. *BMC psychology*, 9, 1–18.
- Alnæs, R. (1964). Therapeutic application of the change in consciousness produced by psycholytica (lsd, psilocyryn, etc.) 1: The Psychedelic Experience in the Treatment of Neurosis. *Acta Psychiatrica Scandinavica*, 39(S180), 397–409.
- Anandarajah, G., & Hight, E. (2001). Spirituality and medical practice: using the HOPE questions as a practical tool for spiritual assessment. *Am Fam Physician*, 63(1), 81–89.
- Andersen, K. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. *Acta Psychiatrica Scandinavica*, 143(2), 101–118.
- Angelakis, I., & Pseftogianni, F. (2021). Association between obsessive-compulsive and related disorders and experiential avoidance: A systematic review and meta-analysis. *Journal of psychiatric research*, 138, 228–239.
- Averill, L. A., & Abdallah, C. G. (2022). Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. *Expert Opinion on Investigational Drugs*, 31(2), 133–137.

- Bache, C. M. (2021). The Challenges of Integrating an Extreme Psychedelic Journey. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Bache, C. M., & Laszlo, E. (2019). *LSD and the Mind of the Universe: Diamonds from Heaven*. Inner Traditions/Bear. https://books.google.cz/books?id=v_v5wgEACAAJ
- Baker, E. F. (1964). The use of lysergic acid diethylamide (LSD) in psychotherapy. *Canadian Medical Association Journal*, 91(23), 1200.
- Balboni, T. A., VanderWeele, T. J., Doan-Soares, S. D., Long, K. N. G., Ferrell, B. R., Fitchett, G., Koenig, H. G., Bain, P. A., Puchalski, C., Steinhauer, K. E., Sulmasy, D. P., & Koh, H. K. (2022). Spirituality in Serious Illness and Health. *Jama*, 328(2), 184–197. <https://doi.org/10.1001/jama.2022.11086>
- Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. *Journal of Psychopharmacology*, 30(12), 1279–1295.
- Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. *Journal of Psychopharmacology*, 29(11), 1182–1190.
- Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. *Personality and individual differences*, 117, 155–160.
- Bateson, G. (1972). Double bind. *Steps to an Ecology of Mind*, 276.
- Bathje, G. J., Majeski, E., & Kudowor, M. (2022). Psychedelic integration: An analysis of the concept and its practice. *Frontiers in Psychology*, 13.
- Bauer, A. S., & Johnson, T. J. (2019). Conceptual overlap of spirituality and religion: An item content analysis of several common measures. *Journal of Spirituality in Mental Health*, 21(1), 14–36. <https://doi.org/10.1080/19349637.2018.1437004>
- Beck, J. S., & Fleming, S. (2021). A brief history of Aaron T. Beck, MD, and cognitive behavior therapy. *Clinical psychology in Europe*, 3(2).
- Beisser, A. (1970). The paradoxical theory of change. *Gestalt therapy now*, 1(1), 77–80.
- Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. *Journal of Humanistic Psychology*, 57(4), 354–388.
- Benda, J. (2024). *Všimavost a Já: Od sebeléčení k sebezpřesahování*. Portál.
- Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. *Biological psychiatry*, 47(4), 351–354.
- Boadella, D. (2015). *Lifestreams: An introduction to biosynthesis*. Routledge.
- Bob, P. (2008). *Brain and dissociated mind*. Nova Biomedical Books.
- Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. *Journal of Psychopharmacology*, 29(3), 289–299.
- Bogenschutz, M. P., & Ross, S. (2017). Therapeutic Applications of Classic Hallucinogens. *Curr Top Behav Neurosci*. https://doi.org/10.1007/7854_2016_464
- Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O'Donnell, K., Owens, L. T., & Podrebarac, S. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry*, 79(10), 953–962.
- Bourzat, F., & Hunter, K. (2019). *Consciousness Medicine: Indigenous Wisdom, Entheogens, and Expanded States of Consciousness for Healing and Growth*. North Atlantic Books.
- Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013). Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. *Psychopharmacology*, 230, 415–424.
- Bowlby, J. (1969). *Attachment and loss*. Random House.
- Boyesen, G. (2014). How I developed biodynamic psychotherapy. In *About a Body* (s. 132–138). Routledge.
- Braun, J. (2021). Impact of Personal Psychedelic Experiences in Clinical Practice. In *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Brennan, W., & Belser, A. B. (2022). Models of psychedelic-assisted psychotherapy: A contemporary assessment and an introduction to EMBARK, a transdiagnostic, trans-drug model. *Frontiers in Psychology*, 13.
- Brown, K. W., & Ryan, R. M. (2003). The benefits of being present: mindfulness and its role in psychological well-being. *Journal of personality and social psychology*, 84(4), 822.
- Buber, M. (2008). *I and Thou*. Howard Books.
- Buller, K., & Moore, J. (2019). Integration workbook: Planting seeds for growth and change. *Psychedelics Today*.
- Callaway, J. C., & Grob, C. S. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. *Journal of psychoactive drugs*, 30(4), 367–369.
- California Institute of Integral Studies. (n.d.). *California Institute of Integral Studies*. <https://ciis.edu>
- Campbell, J. (2003). *The hero's journey: Joseph Campbell on his life and work* (Vol. 7). New World Library.
- Campo, W. M., & Yali, A. M. (2025). Psychedelic use and psychological flexibility: The role of meaningful intention and decentering. *Journal of Psychedelic Studies*, 9(1), 31–44.

- Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. *Journal of Psychopharmacology*, *30*(12), 1268–1278.
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. *N Engl J Med*, *384*(15), 1402–1411. <https://doi.org/10.1056/NEJMoa2032994>
- Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2017). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology (Berl)*. <https://doi.org/10.1007/s00213-017-4771-x>
- Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry*. [https://doi.org/10.1016/S2215-0366\(16\)30065-7](https://doi.org/10.1016/S2215-0366(16)30065-7)
- Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., & Murphy, K. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proceedings of the National Academy of Sciences*, *109*(6), 2138–2143.
- Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. *Pharmacol Rev*, *71*(3), 316–344.
- Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. *Neuropsychopharmacology*, *42*(11), 2105–2113.
- Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015). LSD enhances suggestibility in healthy volunteers. *Psychopharmacology*, *232*, 785–794.
- Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. *Front Hum Neurosci*, *8*, 20. <https://doi.org/10.3389/fnhum.2014.00020>
- Carhart-Harris, R. L., & Nutt, D. J. (2017). Serotonin and brain function: a tale of two receptors. *Journal of Psychopharmacology*, *31*(9), 1091–1120.
- Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., & Murphy, K. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Scientific reports*, *7*(1), 1–11.
- Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. *Journal of Psychopharmacology*, *32*(7), 725–731.
- Carpenter, W. (2019). The Aha! moment: The science behind creative insights. In *Toward super-creativity-improving creativity in humans, machines, and human-machine collaborations*. IntechOpen.
- Cink, V. (2022). *Psychedelika a psychonautika: Mechanismy účinku, etnobotanika, historie a psychoterapie*. I. Dybbuk.
- Cleary, K. (2012, 2. dubna). *Spirálová cesta změny*. GoodTherapy. <https://www.goodtherapy.org/blog/the-spiral-path-of-change-0402124>
- Cohen, I. (2017). *Re-turning to wholeness: The psycho-spiritual integration process of Ayahuasca ceremonies in Western participants from a Jungian Perspective*. California Institute of Integral Studies.
- Cohen, S. (1985). LSD: The varieties of psychotic experience. *Journal of psychoactive drugs*, *17*(4), 291–296.
- Cohen, S., & Ditman, K. S. (1963). Prolonged adverse reactions to lysergic acid diethylamide. *Archives of general psychiatry*, *8*(5), 475–480.
- Cole, B. S., Hopkins, C. M., Tisak, J., Steel, J. L., & Carr, B. I. (2008). Assessing spiritual growth and spiritual decline following a diagnosis of cancer: reliability and validity of the spiritual transformation scale. *Psychooncology*, *17*(2), 112–121. <https://doi.org/10.1002/pon.1207>
- Dakic, V., Minardi Nascimento, J., Costa Sartore, R., Maciel, R. d. M., de Araujo, D. B., Ribeiro, S., Martins-de-Souza, D., & Rehen, S. K. (2017). Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. *Scientific reports*, *7*(1).
- Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. *Journal of contextual behavioral science*, *15*, 39–45.
- Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021a). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. *JAMA Psychiatry*, *78*(5), 481–489.
- Davis, A. K., Barrett, F. S., So, S., Gukasyan, N., Swift, T. C., & Griffiths, R. R. (2021b). Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. *Journal of Psychopharmacology*, *35*(4), 437–446.
- de Brito Sena, M. A., Damiano, R. F., Lucchetti, G., & Peres, M. F. P. (2021). Defining Spirituality in Healthcare: A Systematic Review and Conceptual Framework. *Front Psychol*, *12*. <https://doi.org/10.3389/fpsyg.2021.756080>
- De Vos, C. M., Mason, N. L., & Kuypers, K. P. (2021). Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. *Frontiers in Psychiatry*, *12*.

- DeBonis, K. (2024). Revisiting psychiatry's relationship with spirituality. *Front Psychiatry, 15*. <https://doi.org/10.3389/fpsy.2024.1441922>
- Dehestani, S., Mohammadpour, A. H., Sadjadi, S. A., Sathyapalan, T., & Sahebkar, A. (2023). Clinical use of ketamine in psychiatric disorders. *Annales Médico-psychologiques, revue psychiatrique, 181*(6), 495–508.
- Descending the Mountain. (n.d.). *Descending the Mountain*. <https://descendingthemountain.org>
- Dittrich, A. (1998). The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. *Pharmacopsychiatry, 31*(S 2), 80–84.
- Dittrich, A., Lamparter, D., & Maurer, M. (2010). 5D-ASC: Questionnaire for the assessment of altered states of consciousness. *A short introduction*. PSIN PLUS.
- Doblin, R. (2002). A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. *Journal of psychoactive drugs, 34*(2), 185–194.
- Dorazilová, A., Tylš, F., & Kopeček, M. (2020). Hranice psychopatologie : Psychotické symptomy v duševní nemoci a ve zdraví. *Psychiatrie, 2020, 24*(3), 121–126.
- Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. *Journal of psychoactive drugs, 51*(2), 189–198.
- Dresler, M., Wehrle, R., Spoormaker, V. I., Koch, S. P., Holsboer, F., Steiger, A., Obrig, H., Sämann, P. G., & Czisch, M. (2012). Neural correlates of dream lucidity obtained from contrasting lucid versus non-lucid REM sleep: a combined EEG/fMRI case study. *Sleep, 35*(7), 1017–1020.
- Dupuis, D. (2021). Psychedelics as tools for belief transmission. Set, setting, suggestibility, and persuasion in the ritual use of hallucinogens. *Frontiers in Psychology, 12*.
- Dupuis, D. (2022). The socialization of hallucinations: cultural priors, social interactions, and contextual factors in the use of psychedelics. *Transcultural Psychiatry, 59*(5), 625–637.
- Dupuis, D., & Veissière, S. (2022). Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos. *Transcult Psychiatry, 59*(5), 571–578.
- Dyck, E., & Elcock, C. (Eds.). (2023). *Expanding mindscapes: A global history of psychedelics*. The MIT Press.
- Earleywine, M., Low, F., Lau, C., & De Leo, J. (2022). Integration in psychedelic-assisted treatments: Recurring themes in current providers' definitions, challenges, and concerns. *Journal of Humanistic Psychology*.
- Ecker, B., Tivic, R., & Hulley, L. (2024). *Unlocking the emotional brain: Memory reconsolidation and the psychotherapy of transformational change*. Taylor & Francis.
- Ecker, B., & Vaz, A. (2022). Memory reconsolidation and the crisis of mechanism in psychotherapy. *New Ideas in Psychology, 66*.
- Edsinger, E., & Dölen, G. (2018). A conserved role for serotonergic neurotransmission in mediating social behavior in octopus. *Current Biology, 28*(19), 3136–3142.
- Eisner, B. G., & Cohen, S. (1958). Psychotherapy with lysergic acid diethylamide. *The Journal of nervous and mental disease, 127*(6), 528–539.
- El-Seedi, H. R., De Smet, P. A., Beck, O., Possnert, G., & Bruhn, J. G. (2005). Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of *Lophophora* from Texas. *Journal of ethnopharmacology, 101*(1–3), 238–242.
- Eliade, M. (2018). *The myth of the eternal return: Cosmos and history* (Vol. 46). Princeton university press.
- Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart-Harris, R. L. (2018). Effects of psilocybin therapy on personality structure. *Acta Psychiatr Scand*. <https://doi.org/10.1111/acps.12904>
- Evans, J. (2023). 'More evolved than you': Evolutionary spirituality as a cultural frame for psychedelic experiences. *Front Psychol, 14*. <https://doi.org/10.3389/fpsyg.2023.1103847>
- Fadiman, J. (2011). *The psychedelic explorer's guide: Safe, therapeutic, and sacred journeys*. Simon and Schuster.
- Feldman, R. (2020). What is resilience: an affiliative neuroscience approach. *World Psychiatry, 19*(2), 132–150. <https://doi.org/10.1002/wps.20729>
- Feldmar, A. (2021). On the Therapeutic Stance during Psychedelic Psychotherapy. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021). Substance-induced psychoses: an updated literature review. *Frontiers in Psychiatry, 12*.
- Fischer, F. M. (2019). *Therapy with substance: Psycholytic psychotherapy in the twenty-first century*.
- Fischer, F. M. (2023). The Weekend Workshop. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Flanagan, O., & Graham, G. (2017). Truth and Sanity: Positive Illusions, Spiritual Delusions, and Metaphysical Hallucinations. In J. Poland & S. Tekin (Eds.), *Extraordinary Science and Psychiatry: Responses to the Crisis in Mental Health Research* (s. 293–314). The MIT Press. <https://doi.org/10.7551/mitpress/9780262035484.003.0013>
- Flückiger, C., Del Re, A. C., Wampold, B. E., & Horvath, A. O. (2018). The alliance in adult psychotherapy: A meta-analytic synthesis. *Psychotherapy, 55*(4), 316.
- Fluence. (n.d.). *Fluence Training*. <https://fluencetraining.com>
- Ford, J. G. (1991). Rogerian self-actualization: A clarification of meaning. *Journal of Humanistic Psychology, 31*(2), 101–111.
- Fox, J., Cashwell, C. S., & Picciotto, G. (2017). The opiate of the masses: Measuring spiritual bypass and its relationship to spirituality, religion, mindfulness, psychological distress, and personality. *Spirituality in Clinical Practice, 4*(4), 274.

- Francesetti, G., & Roubal, J. (2020). Field theory in contemporary gestalt therapy, part 1: Modulating the therapist's presence in clinical practice. *Gestalt Review*, 24(2), 113–136.
- Frankl, V. E. (1994). *Člověk hledá smysl: úvod do logoterapie*. Psychoanalytické nakladatelství.
- Freud, S., & Strachey, J. E. (1964). The standard edition of the complete psychological works of Sigmund Freud. Hogarth Press.
- Gaddum, J. (1953). Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. *The Journal of physiology*, 121(1), 15P.
- Gandy, S. (2019). Psychedelics and potential benefits in “healthy normals”: A review of the literature. *Journal of Psychedelic Studies*, 3(3), 280–287.
- Gandy, S., Forstmann, M., Carhart-Harris, R. L., Timmermann, C., Luke, D., & Watts, R. (2020). The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. *Health Psychology Open*, 7(2).
- Garcia-Romeu, A., & Richards, W. A. (2018). Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. *International Review of Psychiatry*, 30(4), 291–316.
- Garland, E. L., Geschwind, N., Peeters, F., & Wichers, M. (2015). Mindfulness training promotes upward spirals of positive affect and cognition: multilevel and autoregressive latent trajectory modeling analyses. *Frontiers in Psychology*, 6, 15.
- Gasser, P. (1996). Die psycholytische psychotherapie in der Schweiz von 1988 bis 1993. *Archives suisses de neurologie et de psychiatrie*, 147, 59–66.
- Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. *J Psychopharmacol*, 29(1), 57–68.
- Geraerts, E., Schooler, J. W., Merckelbach, H., Jelicic, M., JA Hauer, B., & Ambadar, Z. (2007). The reality of recovered memories: Corroborating continuous and discontinuous memories of childhood sexual abuse. *Psychological Science*, 18(7), 564–568.
- Geyer, M. A., & Vollenweider, F. X. (2008). Serotonin research: contributions to understanding psychoses. *Trends Pharmacol Sci*, 29(9), 445–453.
- Glass, L., & Mackey, M. C. (1988). *From clocks to chaos: The rhythms of life*. Princeton University Press.
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., & Bruschi, D. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. *New England Journal of Medicine*, 387(18), 1637–1648.
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Chai-Rees, J., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., & Hellerstein, D. J. (2024a). The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. *Journal of affective disorders*.
- Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2024b). Must psilocybin always “assist psychotherapy”? *American Journal of Psychiatry*, 181(1), 20–25.
- Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021). Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. *Frontiers in Psychology*, 12.
- Granqvist, P. (2024). SYMPOSIUM Exploring the intersection of psychedelics and attachment theory [přednáška]. ICPR conference, Harleem.
- Granqvist, P., & Kirkpatrick, L. A. (2013). Religion, spirituality, and attachment. In K. I. Pargament, J. J. Exline, & J. W. Jones (Eds.), *APA handbook of psychology, religion, and spirituality* (Roč. 1): Context, theory, and research (s. 139–155). American Psychological Association.
- Green, A. R., Mehan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003). The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, “ecstasy”). *Pharmacol Rev*, 55(3), 463–508.
- Greń, J., Gorman, I., Ruban, A., Tylš, F., Bhatt, S., & Aixalà, M. (2023a). Call for evidence-based psychedelic integration. *Experimental and Clinical Psychopharmacology*.
- Greń, J., Tylš, F., Lasocik, M., & Kiraly, C. (2023b). Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists. *Frontiers in Psychology*, 14.
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol*, 30(12), 1181–1197. <https://doi.org/10.1177/0269881116675513>
- Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *Journal of Psychopharmacology*, 22(6), 621–632.
- Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology (Berl)*, 187(3), 268–283; discussion 284–292. <https://doi.org/10.1007/s00213-006-0457-5>
- Grinspoon, L., & Bakalar, J. B. (1979). *Psychedelic drugs reconsidered* (Vol. 168). Basic Books.
- Grinspoon, L., & Doblin, R. (2001). Psychedelics as catalysts of insight-oriented psychotherapy. *Social Research*, 677–695.
- Grof, C. (1992). *The stormy search for the self: A guide to personal growth through transformational crisis*. Penguin.
- Grof, S. (1970). The use of LSD in psychotherapy. *Journal of Psychedelic Drugs*, 3(1), 52–62.
- Grof, S. (1976). *Realms of the Human Unconsciousness: Observations From LSD Research*. Dutton.

- Grof, S. (1980). *LSD psychotherapy*. Hunter House.
- Grof, S. (2019a). *Psychology of the future: Lessons from modern consciousness research*. State University of New York Press.
- Grof, S. (2019b). *The Way of Psychonaut* (Vol. I–II). MAPS.
- Grof, S., & Grofova, C. (2011). *Holotropní dýchání*. Holos.
- Grossman, P., Niemann, L., Schmidt, S., & Walach, H. (2004). Mindfulness-based stress reduction and health benefits: A meta-analysis. *Journal of psychosomatic research*, 57(1), 35–43.
- Gründer, G., Brand, M., Mertens, L. J., Jungaberle, H., Kärtner, L., Scharf, D. J., Spangemacher, M., & Wolff, M. (2024). Treatment with psychedelics is psychotherapy: beyond reductionism. *The Lancet Psychiatry*, 11(3), 231–236.
- Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. *Journal of Psychopharmacology*, 36(2), 151–158.
- Guss, J., Krause, R., & Slosower, J. (2020). The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame).
- Haijen, E. C., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D., & Lorenz, R. (2018). Predicting responses to psychedelics: a prospective study. *Frontiers in pharmacology*, 9, 897.
- Hakomi Institute. (n.d.). *Hakomi Institute*. <https://hakomiinstitute.com>
- Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. *Behavioural brain research*, 277, 99–120.
- Halpern, J. H., Lerner, A. G., & Passie, T. (2018). A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. *Behavioral neurobiology of psychedelic drugs*, 333–360.
- Harman, H. (2023). Set and Setting, Facilitator Presence, and Bodywork. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Harner, M., & Harner, S. (2000). Core practices in the shamanic treatment of illness. *Shamanism*, 13(1–2), 19–30.
- Harris, R. (2021). Ayahuasca and Psychotherapy. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. *Journal of Psychopharmacology*, 30(12), 1259–1267.
- Hartogsohn, I. (2018). The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. *Frontiers in neuroscience*, 12, 129.
- Hartogsohn, I. (2020). *American trip: set, setting, and the psychedelic experience in the twentieth century*. MIT Press.
- Harvey, R. (2021). Training Psychedelic Therapists. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Hausner, M., & Segal, E. (2009). *LSD: The highway to mental health*. ASC Books.
- Hayes, A. M., Laurenceau, J.-P., Feldman, G., Strauss, J. L., & Cardaciotto, L. (2007). Change is not always linear: The study of nonlinear and discontinuous patterns of change in psychotherapy. *Clinical psychology review*, 27(6), 715–723.
- Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (2011). *Acceptance and commitment therapy: The process and practice of mindful change*. Guilford press.
- Heidegger, M. (2013). *Věk obrazu světa*. Oikoymenh.
- Hemsley, D., & Ward, E. (1985). Individual differences in reaction to the abuse of LSD. *Personality and individual differences*, 6(4), 515–517.
- Hilgard, E. R. (1985). Conscious and Unconscious Process in Hypnosis. In *Modern Trends in Hypnosis* (s. 29–40). Springer.
- Hilgard, E. R. (2017). Divided consciousness in hypnosis: The implications of the hidden observer. In *Hypnosis* (s. 45–80). Routledge.
- Hill, S. (2021). Daimonic experience and the psyche's archetypal self-care system. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states* (s. 89–104). Park Street Press.
- Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics: A systematic review and meta-analysis. *JAMA Psychiatry*.
- Hofmann, A. (1980). *LSD, My Problem Child*. McGraw-Hill.
- Holas, P., & Kamińska, J. (2023). Mindfulness meditation and psychedelics: potential synergies and commonalities. *Pharmacological Reports*, 75(6), 1398–1409.
- Hood, R. W., Morris, R. J., & Watson, P. J. (1993). Further Factor Analysis of Hood's Mysticism Scale. *Psychological Reports*, 73(3_suppl), 1176–1178. <https://doi.org/10.2466/pr0.1993.73.3f.1176>
- Horáček, J. (2020). *Model Ketaminem asistované psychoterapie (KAP)* [interní manuál]. Psyon.
- Horáček, J. (2024). *Lidé si vírou zablokovali možnost posunout se*. [interview]. Tvar. <https://itvar.cz/lide-si-virou-zablokovali-moznost-posunout-se>
- Horáček, J., Brunovský, M., Kopeček, M., Španiel, F., Mohr, P., Rodriguez, M., Seifertová, D., Novák, T., & Bělohlávek, O. (2004). Chronické akustické verbální halucinace při temporální epilepsii. Kazuistická studie EEG, qEEG a 18FDG PET. *Psychiatrie*, 8(3), 225–230.
- Horáček, J., & Drtinová, D. (2021). *Vědomí a realita: O mozku, duševní nemoci a společnosti*. Vyšehrad.
- Horton, D. M., Morrison, B., & Schmidt, J. (2021). Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. *American journal of psychotherapy*, 74(4), 140–149.

- Huang, M.-C., & Lin, S.-K. (2020). Ketamine abuse: past and present. *Ketamine: From abused drug to rapid-acting antidepressant*, 1–14.
- Husserl, E. (1913). Ideen zu einer reinen Phänomenologie und phänomenologischen Philosophie. *Erstes Buch: Allgemeine Einführung in die reine Phänomenologie*, 1, 1–3.
- Huxley, A. (1968). *The doors of perception*. Chatto and Windus London.
- Cherniak, A. D., Gruneau Brulin, J., Mikulincer, M., Östlind, S., Carhart-Harris, R., & Granqvist, P. (2023). Psychedelic science of spirituality and religion: An attachment-informed agenda proposal. *The International Journal for the Psychology of Religion*, 33(4), 259–276.
- Cholden, L. S., Kurland, A., & Savage, C. (1955). Clinical reactions and tolerance to LSD in chronic schizophrenia. *The Journal of nervous and mental disease*, 122(3), 211–221.
- Jacobi, J. (2013). *Psychology of CG Jung*. Routledge.
- James, E., Robertshaw, T. L., Hoskins, M., & Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. *Human Psychopharmacology: Clinical and Experimental*, 35(5), e2742.
- Johansen, P.-Ø., & Krebs, T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. *Journal of Psychopharmacology*, 29(3), 270–279.
- Johnson, M. W. (2021). Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine. *ACS pharmacology & translational science*, 4(2), 578–581. <https://doi.org/10.1021/acscptsci.0c00198>
- Johnson, M. W. (2022). Classic psychedelics in addiction treatment: The case for psilocybin in tobacco smoking cessation. *Disruptive psychopharmacology*, 213–227.
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology*, 28(11), 983–992.
- Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. *Pharmacology & therapeutics*, 197, 83–102.
- Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. *Journal of Psychopharmacology*, 22(6), 603–620.
- Jones, L. M. (2021). Underground Psychedelic Psychotherapy. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Joyce, P., & Sills, C. (2024). *Základní dovednosti v gestalt psychoterapii*. Portál.
- Jung, C. G. (2012). *Man and his symbols*. Bantam.
- Jylkkä, J. (2024). *How to evaluate the rationality or delusionality of psychedelically induced changes in metaphysical beliefs and worldviews?* [přednáška]. ICPR conference, Haarlem.
- Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. (2018). The hidden therapist: evidence for a central role of music in psychedelic therapy. *Psychopharmacology (Berl)*, 235(2), 505–519. <https://doi.org/10.1007/s00213-017-4820-5>
- Karaki, S., Becamel, C., Murat, S., La Cour, C. M., Millan, M. J., Prezeau, L., Bockaert, J., Marin, P., & Vandermoere, F. (2014). Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. *Molecular & Cellular Proteomics*, 13(5), 1273–1285.
- Kettner, H., Rosas, F. E., Timmermann, C., Kaertner, L., Carhart-Harris, R., & Roseman, L. (2021). Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. *Frontiers in pharmacology*, 12.
- Kirlić, N., Lennard-Jones, M., Atli, M., Malievskaia, E., Modlin, N. L., Peck, S. K., Gaillard, A., Goodwin, G. M., & Koelpin, D. (2025). Compass psychological support model for COMP360 psilocybin treatment of serious mental health conditions. *American Journal of Psychiatry*, 182(1), 126–132.
- Klučková, T., Nikolič, M., Tylš, F., Viktorin, V., Vejmla, Č., Viktorinova, M., Bravermanova, A., Androvičová, R., Andrashko, V., & Korčák, J. (2024). The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting. *medRxiv*. <https://doi.org/10.1101/2024.08.26.24311611>
- Knop, V., Tylš, F., & Štáfková, V. (2024, 3.–5. května 2024). *Láska je: stav bytí v terapeutickém poli. Když se Gestalt terapeut stává nástrojem pole v ketaminem asistované psychoterapii* [přednáška]. 7. česká konference gestalt psychoterapie Gestalt lásky, Seč.
- Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022). Psychedelics, mystical experience, and therapeutic efficacy: A systematic review. *Frontiers in Psychiatry*, 13, 917199.
- Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021). Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential? *Front Psychiatry*, 12. <https://doi.org/10.3389/fpsy.2021.661233>
- Kohek, M. (2024). *Navigating the high seas: confronting the challenges of the psychedelic renaissance* [přednáška]. ICPR conference, Haarlem.
- Kokkinou, M., Ashok, A. H., & Howes, O. D. (2018). The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. *Molecular psychiatry*, 23(1), 59–69.
- Kopeček, M., & Andrashko, V. (2022). Racemický ketamin v léčbě rezistentní deprese a poruchy. Od výzkumu ke klinické off-label aplikaci. *Psychiatrie*, 26(4), 10.
- Korčák, J., Tylš, F., & Horáček, J. (2019). Psilocybin: farmakologie, fenomenologie a teorie účinku. *Psychiatrie*, 23(1), 11–20.
- Kornfield, J. (2009). *Po extázi prádelna: Výzvy a úskalí, jež člověku přináší duchovní život*. Eminent.

- Kozák, J. A. (2017). Psychedelický rituál. In F. Tylš (Ed.), *Fenomén psychedelie: Subjektivní popisy zážitků z experimentální intoxikace psilocybinem doplněné pohledy výzkumníků* (s. 208). Dybbuk.
- Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. *Journal of Psychopharmacology*, 26(7), 994–1002.
- Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and mental health: a population study. *PLoS One*, 8(8), e63972.
- Krystal, J. H., D'Souza, D. C., Petrakis, I. L., Belger, A., Berman, R. M., Charney, D. S., Abi-Saab, W., & Madonick, S. (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. *Harvard review of psychiatry*, 7(3), 125–143.
- Kwan, A. T., Lakhani, M., Singh, G., Le, G. H., Wong, S., Teopiz, K. M., Dev, D. A., Manku, A. S., Sidhu, G., & McIntyre, R. S. (2024). Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis. *CNS spectrums*, 1–8.
- Le Poidevin, R. (2007). *The images of time: An essay on temporal representation*. Oxford University Press.
- Leary, T., Litwin, G. H., & Metzner, R. (1963). Reactions to psilocybin administered in a supportive environment. *The Journal of nervous and mental disease*, 137(6), 561–573.
- Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015). Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. *Human brain mapping*, 36(8), 3137–3153.
- Letheby, C. (2021). *Philosophy of Psychedelics*. Oxford University Press. <https://doi.org/10.1093/med/9780198843122.001.0001>
- Letcher, A. (2007). Mad thoughts on mushrooms: Discourse and power in the study of psychedelic consciousness. *Anthropology of Consciousness*, 18(2), 74–98.
- Leuner, H. (1969). Guided affective imagery (gai) a method of intensive psychotherapy. *American journal of psychotherapy*, 23(1), 4–22.
- Leuner, H. (1981). *Halluzinogene: psychische Grenzzustände in Forschung und Psychotherapie*. Hogrefe AG.
- Levin, A. W., Lancelotta, R., Sepeda, N. D., Gukasyan, N., Nayak, S., Wagener, T. L., Barrett, F. S., Griffiths, R. R., & Davis, A. K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. *PLoS One*, 19(3), e0300501.
- Levine, J., & Ludwig, A. M. (1966). The hypnodelic treatment technique. *International Journal of Clinical and Experimental Hypnosis*, 14(3), 207–215.
- Levine, J., Ludwig, A. M., & Lyle Jr, W. H. (1963). The controlled psychedelic state. *American Journal of Clinical Hypnosis*, 6(2), 163–164.
- Levine, P. A. (1997). *Waking the tiger: Healing trauma: The innate capacity to transform overwhelming experiences*. North Atlantic Books.
- Liechti, M. E., & Vollenweider, F. X. (2001). Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. *Human Psychopharmacology: Clinical and Experimental*, 16(8), 589–598.
- Lowen, A. (1989). Bioenergetic analysis. *Current psychotherapies*, 572–583.
- Lukoff, D., Lu, F., & Turner, R. (1998). From spiritual emergency to spiritual problem: The transpersonal roots of the new DSM-IV category. *Journal of Humanistic Psychology*, 38(2), 21–50.
- Luna, L. E. (1986). *Vegetalismo: shamanism among the mestizo population of the Peruvian Amazon* (Vol. 27). Almqvist & Wiksell International.
- Luo, J., Niki, K., & Phillips, S. (2004). Neural correlates of the 'Aha! reaction'. *Neuroreport*, 15(13), 2013–2017.
- Luoma, J. B., Chwyl, C., Bathje, G. J., Davis, A. K., & Lancelotta, R. (2020a). A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. *Journal of psychoactive drugs*, 52(4), 289–299.
- Luoma, J. B., Pierce, B., & Levin, M. E. (2020b). Experiential avoidance and negative affect as predictors of daily drinking. *Psychology of addictive behaviors*, 34(3), 421.
- Lutkajtis, A., & Evans, J. (2023). Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands. *Journal of Psychedelic Studies*, 6(3), 211–221.
- Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Zarandi, S. S., Sood, A., & Paddy, M. R. (2018). Psychedelics promote structural and functional neural plasticity. *Cell reports*, 23(11), 3170–3182.
- Mabit, J., Giove, R., & Vega, J. (1996). Takiwasi: The use of Amazonian shamanism to rehabilitate drug addicts. *Yearbook of cross-cultural medicine and psychotherapy*, 6, 257–286.
- MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol*, 25(11), 1453–1461. <https://doi.org/10.1177/0269881111420188>
- MacLean, K. A., Leoutsakos, J. M. S., Johnson, M. W., & Griffiths, R. R. (2012). Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. *Journal for the scientific study of religion*, 51(4), 721–737.
- Madsen, M. K. (2018, 6. 10. 2018). *Psilocybin occupancy and modulation of serotonin 2A receptors: PET studies in humans*. Colloquium on Psychedelic Psychiatry Stockholm, Sweden. https://issuu.com/nfpv/docs/cpp2018_programblad_digi
- Majic, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? *J Psychopharmacol*, 29(3), 241–253. <https://doi.org/10.1177/0269881114568040>

- Malec, M. (2020). *Historie psychedelické terapie* [přednáška]. V rámci předmětu *Experimentální psychofarmakologie, psychedelický výzkum a terapie*, 3. lékařská fakulta Univerzity Karlovy. Česká psychedelická společnost (CZEPS).
- Malleson, N. (1971). Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. *The British Journal of Psychiatry*, 118(543), 229–230.
- Martin, A. J. (1957). LSD (lysergic acid diethylamide) treatment of chronic psychoneurotic patients under day-hospital conditions. *International Journal of Social Psychiatry*, 3(3), 188–195.
- Martin, A. J. (1964). A Case of Early Paranoid Psychosis Treated by Lysergic Acid Diethylamide (LSD). *Acta Psychotherapeutica et Psychosomatica*, 119–130.
- Mascher, E. (1967). Psycholytic therapy: statistics and indications. *Neuropsychopharmacology*, 441–444.
- Maslow, A. H. (1959). Cognition of being in the peak experiences. *The Journal of Genetic Psychology*, 94(1), 43–66.
- Maslow, A. H. (1962). Lessons from the peak-experiences. *Journal of Humanistic Psychology*, 2(1), 9–18.
- Maslow, A. H. (1964). *Religions, values, and peak experiences*. Penguin Books Limited.
- Masters, R. A. (2010). *Spiritual bypassing: When spirituality disconnects us from what really matters*. North Atlantic Books.
- Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward synergies of ketamine and psychotherapy. *Frontiers in Psychology*, 13, 868103.
- McGovern H, Grimmer HJ, Doss M, et al. An Integrated theory of false insights and beliefs under psychedelics. PsyArXiv; 2023. <https://doi.org/10.31234/osf.io/97gfw>
- McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., & Kiou, B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. *JAMA Network Open*, 7(6), e2414650–e2414650.
- McNamee, S., Devenot, N., & Buisson, M. (2023). Studying harms is key to improving psychedelic-assisted therapy—participants call for changes to research landscape. *JAMA Psychiatry*, 80(5), 411–412.
- McWilliams, N. (2011). The Psychodynamic Diagnostic Manual: An effort to compensate for the limitations of descriptive psychiatric diagnosis. *Journal of Personality Assessment*, 93(2), 112–122.
- Mednick, S. A., Watson, J. B., Huttunen, M., Cannon, T. D., Katila, H., Machon, R., Mednick, B., Hollister, M., Parnas, J., & Schulsinger, F. (1998). *A two-hit working model of the etiology of schizophrenia*. American Psychological Association.
- Metzner, R. (2022). *Allies for Awakening: Guidelines for Productive and Safe Experiences with Entheogens*. Four Trees Press. <https://books.google.cz/books?id=0ywtzwEACAAJ>
- Miller, W. R., & C'de Baca, J. (2001). *Quantum change: When epiphanies and sudden insights transform ordinary lives*. Guilford Press.
- Millière, R. (2017). Looking for the self: phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. *Frontiers in human neuroscience*, 11, 191130.
- MIND Foundation. (n.d.). *MIND Foundation*. <https://mind-foundation.org>
- Mindell, A. (1985). *Working with the dreaming body*. Routledge & Kegan Paul London.
- Mindell, A. S. (1991). *Moon in the water: The metaskills of process-oriented psychology as seen through the psychotherapeutic work of Arnold Mindell*. The Union Institute.
- Mithoefer, A., Jerome, L., Ruse, J., Doblin, R., Gibson, E., & Marcela O'Alora, G. (2013). *A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder*. Multidisciplinary Association for Psychedelic Studies.
- Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. *Psychopharmacology*, 236, 2735–2745.
- Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. *The Lancet Psychiatry*, 3(5), 481–488. [https://doi.org/10.1016/s2215-0366\(15\)00576-3](https://doi.org/10.1016/s2215-0366(15)00576-3)
- Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., & Emerson, A. (2018). 3,4-methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. *The Lancet Psychiatry*, 5(6), 486–497.
- Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of (+/-)-3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. *Journal of Psychopharmacology*, 25(4), 439–452.
- Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxy-methamphetamine-assisted psychotherapy: a prospective long-term follow-up study. *Journal of Psychopharmacology*, 27(1), 28–39.
- Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., O'Alora G, M., Garas, W., Paleos, C., & Gorman, I. (2023). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. *Focus*, 21(3), 315–328.
- Moore, T. M., Walker, K., Tung, E., Teed, A. R., Hell, F., Kinreich, S., Jung, R., Abdel, F., Hanson, R. W., & Ahmed, S. S. (2025). Combined ketamine and psychotherapy provide

no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. *Journal of affective disorders*, 381, 233–241.

Moreira-Almeida, A., Sharma, A., van Rensburg, B. J., Verhagen, P. J., & Cook, C. C. (2016). WPA Position Statement on Spirituality and Religion in Psychiatry. *World Psychiatry*, 15(1), 87–88. <https://doi.org/10.1002/wps.20304>

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *Journal of clinical Psychiatry*, 67(11), 1735–1740.

Morgan, N. L. (2020). Integrating psychedelic experiences utilizing the internal family systems therapeutic model. *International Journal of Social Sciences and Management Review*, 3(4), 257–264.

Mørkved, N., Hartmann, K., Aarsheim, L., Holen, D., Milde, A., Bomyea, J., & Thorp, S. (2014). A comparison of narrative exposure therapy and prolonged exposure therapy for PTSD. *Clinical psychology review*, 34(6), 453–467.

Mowery, T. M., & Garraghty, P. E. (2023). Adult neuroplasticity employs developmental mechanisms. *Frontiers in Systems Neuroscience*, 16, 1086680.

Müller, F., Sauer, T., Hanny, C., Mühlhauser, M., & Lang, U. E. (2025). Suicide of a Patient Shortly After Psilocybin-Assisted Psychedelic Therapy. A Case Report. *Psychiatry Research*, 116381.

Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., & Nutt, D. (2022). Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. *Frontiers in pharmacology*, 12, 788155.

Naranjo, C. (2020). *My Psychedelic Explorations: The Healing Power and Transformational Potential of Psychoactive Substances*. Simon and Schuster.

Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019). Oxytocin-dependent reopening of a social reward learning critical period with MDMA. *Nature*, 569(7754), 116–120.

Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., & Goff, L. A. (2023). Psychedelics reopen the social reward learning critical period. *Nature*, 618(7966), 790–798.

National Library of Medicine. (n.d.). *ClinicalTrials.gov*. <https://clinicaltrials.gov>

Nayak, S. M., & Griffiths, R. R. (2022). A single belief-changing psychedelic experience is associated with increased attribution of consciousness to living and non-living entities. *Frontiers in Psychology*, 13, 852248.

Nayak, S. M., Singh, M., Yaden, D. B., & Griffiths, R. R. (2023). Belief changes associated with psychedelic use. *Journal of Psychopharmacology*, 37(1), 80–92.

Nayak, S. M., White, S. H., Hilbert, S. N., Lowe, M. X., Jackson, H., Griffiths, R. R., Garcia-Romeu, A., & Yaden, D. B. (2024). Psychedelic experiences increase mind perception but do not change atheist-believer status: A prospective longitudinal study. *Journal of psychoactive drugs*, 1–10.

NeuroPerspective. (2011, červenec/srpen). *NeuroPerspective*, No. 194 [PDF]. ISSN 1537–6346.

Nevole, S. (1947). *O čtyřrozměrném vidění: Studie z fysiopathologie smyslu prostorového, se zvláštním zřetelem k experimentální otravě mezkalinem*. Lékařské knihkupectví a nakladatelství.

Nielson, E. M., & Guss, J. (2018). The influence of therapists' first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. *Journal of Psychedelic Studies*, 2(2), 64–73.

Nichols, D. E. (2016). Psychedelics. *Pharmacol Rev*, 68(2), 264–355. <https://doi.org/10.1124/pr.115.011478>

Norcross, J. C. (1990). An eclectic definition of psychotherapy. *What is psychotherapy*, 4, 218–220.

Norcross, J. C. (2011). *Psychotherapy relationships that work: Evidence-based responsiveness*. Oxford University Press.

Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI). *Frontiers in human neuroscience*, 10, 269.

OPEN Foundation. (2023, 28. srpna – 1. září). *Substance, set & setting* [diskusní workshop]. Lorentz Center, Leiden, Nizozemí.

OPEN Foundation. (n.d.). *OPEN Foundation*. <https://open-foundation.org>

O'Reilly, J., & Read, T. (2021). Therapeutic Use of MDMA for Post-Traumatic Stress Disorder. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.

Olson, D. E. (2018). Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. *Journal of experimental neuroscience*, 12, 1179069518800508.

Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M., Raz, A., & Veissière, S. P. (2020). Tripping on nothing: placebo psychedelics and contextual factors. *Psychopharmacology*, 237, 1371–1382.

Ortigo, K. M., & Richards, W. A. (2021). *Beyond the narrow life: a guide for psychedelic integration and existential exploration*. Synergetic Press.

Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. *Annals of the New York academy of sciences*, 66(3), 418–434.

Pahnke, W. N., Kurland, A. A., Unger, S., Savage, C., & Grof, S. (1970). The experimental use of psychedelic (LSD) psychotherapy. *Jama*, 212(11), 1856–1863.

Pahnke, W. N., & Richards, W. A. (1966). Implications of LSD and experimental mysticism. *Journal of Religion and Health*, 5(3), 175–208.

- Páleníček, T. (2024, 8. června). *EEG hyperscanning during an ayahuasca ceremony in the Amazon – a pilot study* [přednáška]. ICPR conference, Haarlem.
- Papaspyrou, M. (2021a). Psychedelics in Private Practice. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Papaspyrou, M. (2021b). Toward an Ecology of Ethics. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Pargament, K. I., Ensing, D. S., Falgout, K., Olsen, H., Reilly, B., Van Haitsma, K., & Warren, R. (1990). God help me: (I): Religious coping efforts as predictors of the outcomes to significant negative life events. *American Journal of Community Psychology, 18*(6), 793–824. <https://doi.org/10.1007/BF00938065>
- Passie, T. (1997). Hanscarl Leuner: Pioneer of hallucinogen research and psycholytic therapy. *Maps Newsletter, 7*, 46–49.
- Passie, T. (2024). A history of the European Medical Society for Psycholytic Therapy (EPT) 1964–1974. *Drug Science, Policy and Law, 10*, 20503245231221154.
- Passie, T. (2024). *Should controlled self-experience with psychedelic drugs be part of the training of psychedelic therapists* [přednáška]. ICPR conference.
- Passie, T., Guss, J., & Krähenmann, R. (2022). Lower-dose psycholytic therapy—a neglected approach. *Frontiers in Psychiatry, 13*, 1020505.
- Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: a review. *CNS neuroscience & therapeutics, 14*(4), 295–314.
- Pavlovič, I. (2020). Integration of altered states of consciousness according to the process oriented psychology. *Soc Health Horiz, 7*(30).
- Payne, J. E., Chambers, R., & Liknaitzky, P. (2021). Combining psychedelic and mindfulness interventions: Synergies to inform clinical practice. *ACS pharmacology & translational science, 4*(2), 416–423.
- Peill, J., Marguilho, M., Erritzoe, D., Barba, T., Greenway, K. T., Rosas, F., Timmermann, C., & Carhart-Harris, R. (2024). Psychedelics and the ‘inner healer’: Myth or mechanism? *Journal of Psychopharmacology, 38*(5), 417–424.
- Peill, J. M., Trinci, K. E., Kettner, H., Mertens, L. J., Roseman, L., Timmermann, C., Rosas, F. E., Lyons, T., & Carhart-Harris, R. L. (2022). Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience. *Journal of Psychopharmacology, 36*(1), 31–45.
- Perls, F., Hefferline, G., & Goodman, P. (1951). Gestalt therapy. *New York, 64*(7), 19–313.
- Pesso, A. (1984). Introduction to Pesso System/Psychomotor. *PBSP: Pesso Boyden System Psychomotor*.
- Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. *Journal of Humanistic Psychology, 57*(5), 450–487.
- Picciotto, G., & Fox, J. (2018). Exploring experts’ perspectives on spiritual bypass: A conventional content analysis. *Pastoral Psychology, 67*, 65–84.
- Picciotto, G., Fox, J., & Neto, F. (2018). A phenomenology of spiritual bypass: Causes, consequences, and implications. *Journal of Spirituality in Mental Health, 20*(4), 333–354.
- Plotkin, B. (2010). *Nature and the human soul: Cultivating wholeness and community in a fragmented world*. New World Library.
- Pollan, M. (2018). *How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence*. Penguin.
- Poulter, B. (2024). Rozhovory. In F. Tylš (Ed.).
- Preller, K. H., & Vollenweider, F. X. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. *Curr Top Behav Neurosci, 36*, 221–256. https://doi.org/10.1007/7854_2016_459
- Prostor integrace. (n.d.). *Prostor integrace*. <https://prostorintegrace.cz>
- Prusak, J. (2016). Differential diagnosis of “Religious or Spiritual Problem” – possibilities and limitations implied by the V-code 62.89 in DSM-5. *Psychiatria Polska, 50*(1), 175–186. <https://doi.org/10.12740/PP/59115>
- Psiket. (n.d.). *Psiket*. <https://psiket.cz>
- PsyCare. (n.d.). *PsyCare*. <https://psycare.cz>
- Psyon. (n.d.). *Psyon*. <https://psyon.cz>
- Razvi, S., & Elfrink, S. (2020). The PSIP model. An introduction to a novel method of therapy: Psychedelic Somatic Interactional Psychotherapy. *J. Psychedelic Psychiatry, 2*(3), 1–24.
- Read, T. (2021a). The Healing Potential of Challenging Psychedelic States. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Read, T. (2021b). Psychedelic Psychotherapy Supervision. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Read, T., & Papaspyrou, M. (2021). *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Reckweg, J. T., van Leeuwen, C. J., Henquet, C., van Amelsvoort, T., Theunissen, E. L., Mason, N. L., Paci, R., Terwey, T. H., & Ramaekers, J. G. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. *Frontiers in Psychiatry, 14*, 1133414.
- Reed, P. G. (1992). An emerging paradigm for the investigation of spirituality in nursing. *Res Nurs Health, 15*(5), 349–357. <https://doi.org/10.1002/nur.4770150505>
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., Biomarkers, W. G. o., & Novel Treatments, a Division of the American Psychiatric Association Council of Research (2020). Psychedelics and psychedelic-assisted psychotherapy. *American Journal of Psychiatry, 177*(5), 391–410.

- Reich, W. (1972). *Character analysis*. Farrar, Straus and Giroux.
- Reisinger, D. (2024). What is spirituality? The challenges of a philosophical definition. *Sophia*. <https://doi.org/10.1007/s11841-024-01034-w>
- Resick, P. (2016). *Cognitive Processing Therapy for PTSD: A Comprehensive Manual*. Guilford Publications.
- Rhead, J. C. (1977). The use of psychedelic drugs in the treatment of severely disturbed children: a review. *Journal of Psychedelic Drugs*, 9(2), 93–101.
- Richards, W. A. (2015). *Sacred knowledge: Psychedelics and religious experiences*. Columbia University Press.
- Richards, W. A. (2021). *Posvátné poznání: Psychedelika a prožitek mystické náboženské zkušenosti* (Vol. 2). Dybbuk.
- Rogers, C. R. (1951). *Client-centered therapy: Its current practice, implications, and theory, with chapters*. Houghton Mifflin Harcourt.
- Rogers, C. R. (1957). The necessary and sufficient conditions of therapeutic personality change. *Journal of consulting psychology*, 21(2), 95.
- Roseman, L. (2021). Psychedelic Peace Building. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. *Frontiers in pharmacology*, 8, 974.
- Roseman, L., Ron, Y., Saca, A., Ginsberg, N., Luan, L., Karkabi, N., Doblin, R., & Carhart-Harris, R. (2021). Relational processes in ayahuasca groups of Palestinians and Israelis. *Frontiers in pharmacology*, 12, 607529.
- Ross, S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. *Psychiatric Clinics of North America*, 35(2), 357–374.
- Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., & Bossis, A. (2021). Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer. *ACS pharmacology & translational science*, 4(2), 553–562.
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzis, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*, 30(12), 1165–1180. <https://doi.org/10.1177/0269881116675512>
- Roubal, J. (2019). *Theory of change in Gestalt therapy clinical work*. Los Libros del CTP.
- Roubal, J., & Francesetti, G. (2022). Field theory in contemporary gestalt therapy part two: paradoxical theory of change reconsidered. *Gestalt Review*, 26(1), 1–33.
- Roubicek, J., & Drvota, S. (1960). Psilocybin, nové fantastikum. *Československá Psychiatrie*, 56, 44–55.
- Roussiau, N., Ollivaud, J., & Galharret, J.-M. (2023). Spirituality, self-esteem and the mechanisms of social and temporal comparison. *Spiritual Psychology and Counseling*, 8(1), 83–102. <https://doi.org/10.37898/spc.2023.8.1.187>
- Rucker, J. J., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present, future. *Neuropharmacology*, 142, 200–218.
- Rucker, J. J., Marwood, L., Ajantaival, R.-L. J., Bird, C., Eriksson, H., Harrison, J., Lennan-Jones, M., Mistry, S., Saldarini, F., & Stansfield, S. (2022). The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomized, placebo-controlled trial involving simultaneous psilocybin administration and preparation. *Journal of Psychopharmacology*, 36(1), 114–125.
- Sabé, M., Sulstarova, A., Glangetas, A., De Pieri, M., Mallet, L., Curtis, L., Richard-Lepouriel, L., Penzenstadler, L., Seragnoli, F., & Thorens, G. (2024). Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. *Molecular psychiatry*, 1–33.
- Salo, J., Jokela, M., Lehtimäki, T., & Keltikangas-Järvinen, L. (2011). Serotonin receptor gene moderates the effect of childhood maternal nurturance on adulthood social attachment. *Genes, Brain and Behavior*, 10(7), 702–709.
- Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E., & De Araujo, D. B. (2017). Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. *International Journal of Neuropsychopharmacology*, 20(9), 698–711.
- Sanders, J. W., & Zylmans, J. (2021). Moving Past Mysticism in Psychedelic Science. *Pharmacol Transl Sci*, 4(3), 1253–1255. <https://doi.org/10.1021/acspsci.1c00097>
- Sandison, R., & Whitelaw, J. (1957). Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. *Journal of Mental Science*, 103(431), 332–343.
- Seikkula, J., & Arnkil, T. E. (2013). *Otevřené dialogy: setkávání sítí klienta v psychosociální práci*. Narativ.
- Shapiro, F. (2017). *Eye movement desensitization and reprocessing (EMDR) therapy: Efficacy, principles, protocols, and procedures*. Guilford Publications.
- Shaw, E., & Woolley, D. (1956). Some serotoninlike activities of lysergic acid diethylamide. *Science*, 124(3212), 121–122.
- Shaw, J. (2016). *The memory illusion: Remembering, forgetting, and the science of false memories*. Random House.
- Shek, D. T. L. (2014). Spirituality, Overview. In A. C. Michalos (Ed.), *Encyclopedia of Quality of Life and Well-Being Research* (s. 6289–6295). Springer Netherlands. https://doi.org/10.1007/978-94-007-0753-5_2832

- k, J. F. E., & Smith, D. E. (1970). Analysis of the LSD flashback. *Journal of Psychedelic Drugs*, 3(1), 13–19.
- nozuka, K., Jerotic, K., Mediano, P., Zhao, A. T., Preller, K. H., Carhart-Harris, R., & Kringsbach, M. L. (2024). Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. *Transl Psychiatry*, 14(1), 485. <https://doi.org/10.1038/s41398-024-03187-1>
- ikuroglou, M., Roseman, L., Wall, M., Nutt, D., Kaelen, M., & Carhart-Harris, R. (2023). Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression. *Journal of Psychopharmacology*, 37(1), 70–79.
- algin, A. T., & Shulgin, A. (1991). *PIHKAL: a chemical love story* (Vol. 963009605). Transform Press Berkeley, CA.
- henberg, E. E. (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. *Front Pharmacol*, 9, 733. <https://doi.org/10.3389/fphar.2018.00733>
- hmid, Y., & Liechti, M. E. (2018). Long-lasting subjective effects of LSD in normal subjects. *Psychopharmacology*, 235, 535–545.
- hutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024). Psychedelic experiences and long-term spiritual growth: a systematic review. *Current Psychology*, 43(32), 26372–26394. <https://doi.org/10.1007/s12144-024-06272-2>
- egel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., & Gratton, C. (2024). Psilocybin desynchronizes the human brain. *Nature*, 632(8023), 131–138.
- ilins, E., Copeland, J., & Dillon, P. (2007). Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. *Australian & New Zealand Journal of Psychiatry*, 41(8), 649–655.
- immler, L. D., & Liechti, M. E. (2018). Pharmacology of MDMA-and amphetamine-like new psychoactive substances. *New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology*, 143–164.
- loan, E., Hall, K., Moulding, R., Bryce, S., Mildred, H., & Staiger, P. K. (2017). Emotion regulation as a transdiagnostic treatment construct across anxiety, depression, substance, eating and borderline personality disorders: A systematic review. *Clinical psychology review*, 57, 141–163.
- Sloshower, J., Skosnik, P. D., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D'Souza, D. C. (2023). Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. *Journal of Psychopharmacology*, 37(7), 698–706.
- Smart, R. G., Storm, T., Baker, E. F., & Solursh, L. (1966). A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior. *Quarterly journal of studies on alcohol*, 27(3), 469–482.
- Smigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019). Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. *Neuroimage*, 196, 207–215.
- Smith, H. (2009). *The World's Religions (Plus)*. HarperOne.
- Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., de Magalhães, F. J., Lafrance, A., Nicholls, D. E., Erritzoe, D., Nutt, D. J., & Carhart-Harris, R. L. (2021). Study protocol for “psilocybin as a treatment for anorexia nervosa: a pilot study”. *Frontiers in Psychiatry*, 12, 735523.
- Stace, W. T. (1960). *Mysticism and Philosophy*. Lippincott.
- Stauffer, C. S., Anderson, B. T., Ortigo, K. M., & Woolley, J. (2020). Psilocybin-assisted group therapy and attachment: observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience. *ACS pharmacology & translational science*, 4(2), 526–532.
- Stiles, W. B., Leach, C., Barkham, M., Lucock, M., Iveson, S., Shapiro, D. A., Iveson, M., & Hardy, G. E. (2003). Early sudden gains in psychotherapy under routine clinic conditions: practice-based evidence. *Journal of consulting and clinical psychology*, 71(1), 14.
- Stolaroff, M. J. (2022). *Secret Chief Revealed, Revised 2nd Edition: Conversations with Leo Zeff, Pioneer in the Underground Psychedelic Therapy Movement*. Multidisciplinary Association for Psychedelic Studies. <https://books.google.cz/books?id=GKHozgEACAAJ>
- Strassman, R. (2000). *DMT: The spirit molecule: A doctor's revolutionary research into the biology of near-death and mystical experiences*. Simon and Schuster.
- Strassman, R. J. (1984). Adverse reactions to psychedelic drugs. A review of the literature. *The Journal of nervous and mental disease*, 172(10), 577–595.
- Strassman, R. J. (1995). Hallucinogenic drugs in psychiatric research and treatment perspectives and prospects. *The Journal of nervous and mental disease*, 183(3), 127–138.
- Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. *Arch Gen Psychiatry*, 51(2), 98–108. <https://doi.org/10.1001/archpsyc.1994.03950020022002>
- Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of psilocybin response in healthy volunteers. *PLoS One*, 7(2), e30800. <https://doi.org/10.1371/journal.pone.0030800>
- Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). *PLoS One*, 5(8), e12412.
- Swanson, L. R. (2018). Unifying Theories of Psychedelic Drug Effects. *Front Pharmacol*, 9, 172. <https://doi.org/10.3389/fphar.2018.00172>
- Tai, S. J., Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R.-L., Winzer, R., Richards, W. A., Reinholdt, F., Richards, B. D., Gasser, P., & Malievskaia, E. (2021). Develop-

- ment and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research. *Frontiers in Psychiatry*, 12, 586682.
- Taylor, S. (2011). *Out of the darkness: From turmoil to transformation*. Hay House, Inc.
- Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021). Psychedelics alter metaphysical beliefs. *Scientific reports*, 11(1), 22166.
- Tobin, B. (2021). Art Therapy and Psychedelic Integration. In T. Read & M. Papaspyrou (Eds.), *Psychedelics and psychotherapy: The healing potential of expanded states*. Park Street Press.
- Turner, E. (2012). *Communitas: The anthropology of collective joy*. Springer.
- Turner, V., Abrahams, R., & Harris, A. (2017). *The ritual process: Structure and anti-structure*. Routledge.
- Warog, B. M., & Page, I. H. (1953). Serotonin content of some mammalian tissues and urine and a method for its determination. *American Journal of Physiology-Legacy Content*, 175(1), 157–161.
- Wylš, F. (2017). *Fenomén psychedelie: Subjektivní popisy zážitků z experimentální intoxikace psilocybinem doplněné pohledy výzkumníků*. Dybbuk.
- Wylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin – summary of knowledge and new perspectives. *Eur Neuropsychopharmacol*, 24(3), 342–356. <https://doi.org/10.1016/j.euro-neuro.2013.12.006>
- Wylš, F., Páleníček, T., & Horáček, J. (2016). Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets. In V. R. Preedy (Ed.), *Neuropathology of Drug Addictions and Substance Misuse* (s. 1182), Academic Press.
- Wylš, F. (2017). *Elektroencefalografické změny v animálním serotonergním modelu psychózy - studium EEG konektivity mozku ve vztahu k chování*. Univerzita Karlova, 3. lékařská fakulta, Klinika psychiatrie a lékařské psychologie 3. LF UK a NÚDZ. <http://hdl.handle.net/20.500.11956/2132>
- Wylš, F. (2022). Psilocybinem asistovaná psychoterapie. In V. Cink (Ed.), *Psychedelika a psychonautika: Mechanismy účinku, etnobotanika, historie a psychoterapie. I*. Dybbuk.
- Wylš, F. (2025). Ketaminem asistovaná psychoterapie v klinické praxi. *Psychiatrie*, 29(1), 8.
- Yrutia, J., Anderson, B. T., Belouin, S. J., Berger, A., Griffiths, R. R., Grob, C. S., Henningfield, J. E., Labate, B. C., Maier, L. J., Maternowska, M. C., Weichold, F., Yaden, D. B., & Magar, V. (2023). Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional Knowledge Systems: Towards Integrative Community-Based Approaches in Global Health. *J Psychoactive Drugs*, 55(5), 523–538. <https://doi.org/10.1080/02791072.2023.2258367>
- Zallersnes, O. M., Dines, A. M., Wood, D. M., Yates, C., Heyerdahl, F., Hovda, K. E., Giraudon, I., & Dargan, P. I. (2016). Psychosis associated with acute recreational drug toxicity: a European case series. *BMC psychiatry*, 16, 1–8.
- van der Hart, O., & Horst, R. (1989). The dissociation theory of Pierre Janet. *Journal of traumatic stress*, 2(4), 397–412.
- Vejmola, C., Syrová, K., Šíchová, K., Koudelka, V., Hubený, J., Kluckova, T., Nikolic, M., Kelemen, E., & Páleníček, T. (2023). Cross-species evidence for psilocin-induced visual hallucinations: rats perceive qualitatively similar changes as humans. *IBRO Neuroscience Reports*, 15, S723.
- Viktorinová, M., & Tylš, F. (2016). Nevědomé procesy lidské mysli-poznatky z psychedelického výzkumu. *Psychiatrie*, 20(2), 100–107.
- Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. *Neuropsychopharmacology*, 19(4), 241–251.
- Vollenweider, F. X., & Geyer, M. A. (2001). A systems model of altered consciousness: integrating natural and drug-induced psychoses. *Brain research bulletin*, 56(5), 495–507.
- Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. *Nature Reviews Neuroscience*, 11(9), 642–651.
- Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. *Nature Reviews Neuroscience*, 21(11), 611–624.
- Voss, U., Holzmann, R., Tuin, I., & Hobson, A. J. (2009). Lucid dreaming: a state of consciousness with features of both waking and non-lucid dreaming. *Sleep*, 32(9), 1191–1200.
- Wagner, A. C., Mithoefer, M. C., Mithoefer, A. T., & Monson, C. M. (2019). Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-methylenedioxymethamphetamine (MDMA): a case example. *Journal of psychoactive drugs*, 51(2), 166–173.
- Wasson, R. G. (1980). *The wondrous mushroom: mycolatry in Mesoamerica*. McGraw-Hill.
- Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. *Journal of Humanistic Psychology*, 57(5), 520–564. <https://doi.org/10.1177/0022167817709585>
- Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., Timmermann, C., Nour, M. M., Kaelen, M., & Nutt, D. (2022). The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. *Psychopharmacology*, 239(11), 3461–3483.
- Watts, R., & Luoma, J. B. (2020). The use of the psychological flexibility model to support psychedelic assisted therapy. *Journal of contextual behavioral science*, 15, 92–102.
- Watzlawick, P. (1984). *The Invented reality: how do we know what we believe we know? (contributions to constructivism)*. Norton.
- Watzlawick, P. (1993). *The language of change: Elements of therapeutic communication*. WW Norton & Company.

- Vatzlawick, P., Bavelas, J. B., & Jackson, D. D. (2011). *Pragmatics of human communication: A study of interactional patterns, pathologies and paradoxes*. WW Norton & Company.
- Vatzlawick, P., Weakland, J. H., & Fish, R. (1976). *Change. Principles of Problem Formation and Problem Resolution*. Norton.
- Vei, M., Wang, L.-f., & Kivlighan Jr, D. M. (2021). Group counseling change process: An adaptive spiral among positive emotions, positive relations, and emotional cultivation/regulation. *Journal of Counseling Psychology*, 68(6), 730.
- Weiss, B., Roseman, L., Giribaldi, B., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2024). Unique psychological mechanisms underlying psilocybin therapy versus escitalopram treatment in the treatment of major depressive disorder. *International Journal of Mental Health and Addiction*, 1–36.
- Velwood, J. (1984). Principles of inner work: Psychological and spiritual. *Journal of Transpersonal Psychology*, 16(1), 63–73.
- Velwood, J. (2002). *Toward a psychology of awakening: Buddhism, psychotherapy, and the path of personal and spiritual transformation*. Shambhala Publications.
- Vestrum, P., & Dufrechou, J. (2019). The psychedelics integration handbook. *Westrum and Dufrechou*.
- Vilber, K. (2007). *Integral spirituality: A startling new role for religion in the modern and postmodern world*. Shambhala Publications.
- Vinkler, P., Gorman, I., & Kočárová, R. (2016). Use of LSD by mental health professionals. In *Neuropathology of drug addictions and substance misuse* (s. 773–781). Elsevier.
- Volff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020). Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. *Frontiers in Psychiatry*, 11, 5.
- Volfson, E. (2023). Psychedelic-supportive psychotherapy: A psychotherapeutic model for, before and beyond the medicine experience. *Journal of Psychedelic Studies*, 6(3), 191–202.
- Volfson, P., & Vaid, G. (2024). Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach. *Frontiers in Psychiatry*, 15, 1209419.
- Volgast, M. (2014). What does the Acceptance and Action Questionnaire (AAQ-II) really measure? *Behavior therapy*, 45(6), 831–839.
- Yaden, D. B., Earp, D., Graziosi, M., Friedman-Wheeler, D., Luoma, J. B., & Johnson, M. W. (2022). Psychedelics and psychotherapy: cognitive-behavioral approaches as default. *Frontiers in Psychology*, 13, 873279.
- Yaden, D. B., & Griffiths, R. R. (2020). The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. *ACS Pharmacol Transl Sci*, 4(2), 568–572. <https://doi.org/10.1021/acspsci.0c00194>
- Yaden, D. B., Le Nguyen, K. D., Kern, M. L., Wintering, N. A., Eichstaedt, J. C., Schwartz, H. A., Buffone, A. E., Smith, L. K., Waldman, M. R., & Hood Jr, R. W. (2017). The noetic quality: A multimethod exploratory study. *Psychology of Consciousness: Theory, Research, and Practice*, 4(1), 54.
- Yaden, D. B., & Newberg, A. (2022). *The Varieties of Spiritual Experience: 21st Century Research and Perspectives*. Oxford University Press. <https://doi.org/10.1093/oso/9780190665678.001.0001>
- Yalom, I. (1981) *Existential Psychotherapy*. In JSTOR (1980), Basic Books.
- Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate Jr, C. A. (2022). Ketamine treatment for depression: a review. *Discover mental health*, 2(1), 9.
- Zamarovský, V. (1965). *Bohové a hrdinové antických bájí*. Mladá fronta.
- Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. *Molecular psychiatry*, 23(4), 801–811.
- Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F., Albuquerque, E. X., Thomas, C. J., & Zarate Jr, C. A. (2018). Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. *Pharmacol Rev*, 70(3), 621–660.
- Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Archives of general psychiatry*, 63(8), 856–864.
- Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. *Journal of affective disorders*, 334, 100–112.
- Zeifman, R. J., Yu, D., Singhal, N., Wang, G., Nayak, S. M., & Weissman, C. R. (2022). Decreases in suicidality following psychedelic therapy: A meta-analysis of individual patient data across clinical trials. *The Journal of clinical psychiatry*, 83(2), 39235.
- Zinnbauer, B. J., Pargament, K. I., Cole, B., Rye, M. S., Butter, E. M., Belavich, T. G., Hipp, K. M., Scott, A. B., & Kadar, J. L. (1997). Religion and Spirituality: Unfuzzifying the Fuzzy. *Journal for the scientific study of religion*, 36(4), 549–564. <https://doi.org/10.2307/1387689>